Research
Hormonal
Retatrutide exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM).
Retatrutide may be an effective treatment option for managing HbA1c and weight in T2DM patients.
StrongSupportsmedium confidence
Retatrutide, in phase-2 trials, exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM).
Why this rating
Based on phase-2 trial data mentioned in the abstract.
Source
Retatrutide: a triple incretin receptor agonist for obesity management
Avik Ray · Expert Opinion on Investigational Drugs · 2023
reviewCited 8×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →